Press Releases

Oct 16, 2018

Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps

- Dupixent significantly reduced nasal polyp size, nasal congestion severity, and need for systemic corticosteroids and/or surgery
Sep 28, 2018

FDA approves Libtayo® (cemiplimab-rwlc) as first and only treatment for advanced cutaneous squamous cell carcinoma

* Libtayo is the third anti-PD-1 approved in the U.S.
Sep 12, 2018

FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events

* FDA also recently approved Praluent label update for some patients currently requiring LDL apheresis therapy
Sep 4, 2018

Sanofi reaches civil settlement with US SEC
Sep 3, 2018

Cablivi™ (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura (aTTP)

- First therapeutic approved for the treatment of aTTP, a rare blood-clotting disorder

Show per page

Print
Email page
RSS